Brief: Valneva Q1 Revenue EUR 30.9 Million
13/05/2026 06:00
May 13 (Reuters) - Valneva Q1 net income EUR -32.1 million. Q1 adjusted EBITDA EUR -18.2 million
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency